Epidemiology and treatment of patients with Chronic rhinosinusitis with nasal polyps in Germany—A claims data study

Abstract

Background There are different levels of severity among patients who suffer from chronic rhinosinusitis with nasal polyps (CRSwNP). In this study, the epidemiology of CRSwNP and severe CRswNP was estimated. Methods A retrospective claim data analysis was conducted on adult CRSwNP patients (ICD‐10: J33), and those classified as severe CRSwNP patients with inadequate disease control (based upon combinations of previous and current treatments) between 2015 and 2019. Prevalence and incidence figures were calculated and extrapolated to the German population. In addition, baseline characteristics and treatment outcomes were analysed. Results Overall, the 5‐year prevalence of adult CRSwNP cases from 2015 to 2019 in Germany was 374,115 cases (about 5500 per million), with 12,989 (about 200 per million) patients being classified as severe CRSwNP with inadequate disease control, whereas 267,880 (about 3900 per million) patients were identified as having an incident CRSwNP diagnosis between 2016 and 2019. From the incident CRSwNP cohort, 80.55% had received at least one intranasal corticosteroid (INCS), 24.27% received at least 1 systemic corticosteroid (SCS), and 17.33% received at least one functional endoscopic sinus surgery (FESS) within 12 months after their incident diagnosis. Conclusion Severe CRSwNP with inadequate disease control affects about 200 per million people in Germany. INCS is the first‐choice treatment for most CRSwNP patients; however, for patients with severe CRSwNP, SCS are prescribed more frequently and long‐term effects of these should be further investigated, especially if despite treatment, adequate disease control cannot be achieved.

Prevalence of Chronic Rhinositis with SARS-CoV-2 Infection in Rhinology-Allergy Clinic Hasan Sadikin General Hospital

“…11 Another study in Germany demonstrated a higher prevalence of CRSwNP in men (approximately 7,200 individual per million) than women (approximately 4,700 individual per million) over five years. 12 Exposure to tobacco smoke plays an active role in increasing chronic rhinosinusitis because it can trigger mucosal changes and damage to nasal cilia and paranasal sinuses. 13 However, an epidemiological study by Ference et al in 2015 stated that the incidence of CRS in women was elevated two times than in men because of hormonal factors.…”

Multidimensional Impact of Dupilumab on Chronic Rhinosinusitis with Nasal Polyps: A Complete Health Technology Assessment of Clinical, Economic, and Non-Clinical Domains

“…To estimate the population eligible for treatment, the prevalence of CRSwNP [22,23] was applied to the Italian adult population residents in 2022 (ISTAT, 2023). Therefore, a funnel of inclusion criteria was applied, estimating the number of Italian patients with severe CRSwNP for whom standards of care were not effective.…”

Ergebnisse einer Umfrage zur aktuellen Behandlung der chronischen Rhinosinusitis mit nasalen Polypen

“…Die CRS ist durch das persistierende Vorliegen von 2 der 4 Kardinalsymptome Nasenatmungsbehinderung, Riechstörung, Gesichtsschmerzen oder Rhinorrhoe über eine minimale Krankheitsdauer von 12 Wochen definiert. Zusätzlich unterscheidet sich die CRS phänotypisch hinsichtlich des Vorliegens nasaler Polypen in die Gruppe mit Polypen (20-30 %, CRSwNP) und ohne Polypen (CRSsNP) [4]. Die Diagnose von Polypen sollte dabei regelhaft endoskopisch gesichert werden [5].…”